Respiratory Syncytial Virus Infections Concept

subject area of

• A Comparison of Respiratory Syncytial Viral Prophylaxis in Multiple Births versus Singletons in the Canadian Registry of Palivizumab  Journal Articles
• A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical Practice  Journal Articles
• A Survey of Parental Knowledge of Respiratory Syncytial Virus and Other Respiratory Infections in Preterm Infants  Journal Articles
• A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)  Journal Articles
• A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection  Journal Articles
• A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age  Journal Articles
• A review of cost–effectiveness of palivizumab for respiratory syncytial virus  Journal Articles
• Absence of detection of RSV and influenza during the COVID-19 pandemic in a Brazilian cohort: Likely role of lower transmission in the community  Journal Articles
• Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada.  Journal Articles
• Achieving control of asthma in preschoolers  Journal Articles
• Adherence and outcomes: a systematic review of palivizumab utilization  Journal Articles
• Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab  Journal Articles
• Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants  Journal Articles
• Are late preterm infants as susceptible to RSV infection as full term infants?  Journal Articles
• Association of Respiratory Viruses with Outcomes of Severe Childhood Pneumonia in Botswana  Journal Articles
• Burden of Severe Respiratory Syncytial Virus Disease Among 33–35 Weeks’ Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons  Journal Articles
• Burden of respiratory syncytial virus hospitalisation among infants born at 32–35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies  Journal Articles
• CARESS  Journal Articles
• CARESS: The Canadian Registry of Palivizumab  Journal Articles
• Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries  Journal Articles
• Changing costs and the impact on RSV prophylaxis  Journal Articles
• Characteristics and Outcomes of Young Children Hospitalized With Laboratory-confirmed Influenza or Respiratory Syncytial Virus in Ontario, Canada, 2009-2014.  Journal Articles
• Characteristics and Outcomes of Young Children Hospitalized With Laboratory-confirmed Influenza or Respiratory Syncytial Virus in Ontario, Canada, 2009–2014  Journal Articles
• Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis  Journal Articles
• Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005–2015)  Journal Articles
• Comparison of Flocked and Rayon Swabs for Collection of Respiratory Epithelial Cells from Uninfected Volunteers and Symptomatic Patients  Journal Articles
• Comparison of Viral Isolation and Multiplex Real-Time Reverse Transcription-PCR for Confirmation of Respiratory Syncytial Virus and Influenza Virus Detection by Antigen Immunoassays  Journal Articles
• Comparison of the Cost of Hospitalization for Respiratory Syncytial Virus Disease Versus Palivizumab Prophylaxis in Canadian Inuit Infants  Journal Articles
• Cost-effectiveness of respiratory syncytial virus prophylaxis in premature infants less than 32 weeks gestational age in Turkey.  Journal Articles
• Cost-effectiveness of wastewater and environmental monitoring of respiratory syncytial virus to guide universal infant immunoprophylaxis in Canada.  Journal Articles
• Current strategies in the prevention of respiratory syncytial virus disease  Journal Articles
• Development and Validation of a Risk Scoring Tool to Predict Respiratory Syncytial Virus Hospitalization in Premature Infants Born at 33 through 35 Completed Weeks of Gestation  Journal Articles
• Development of a Sensitive Loop-Mediated Isothermal Amplification Assay That Provides Specimen-to-Result Diagnosis of Respiratory Syncytial Virus Infection in 30 Minutes  Journal Articles
• Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory‐syncytial‐virus‐related infection in cystic fibrosis children less than 2 years of age?  Journal Articles
• Estimating the Incidence of First RSV Hospitalization in Children Born in Ontario, Canada  Journal Articles
• Expert consensus on palivizumab use for respiratory syncytial virus in developed countries  Journal Articles
• Exploring respiratory syncytial virus prophylaxis for children with all grades of bronchopulmonary dysplasia  Journal Articles
• First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005–2015)  Journal Articles
• Global molecular diversity of RSV – the “INFORM RSV” study  Journal Articles
• Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series  Journal Articles
• High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention  Journal Articles
• Hospitalization for Respiratory Syncytial Virus Illness in Down Syndrome Following Prophylaxis With Palivizumab  Journal Articles
• Hospitalization for Respiratory Syncytial Virus in Children with Down Syndrome Less than 2 Years of Age: A Systematic Review and Meta-Analysis  Journal Articles
• Identifying and Ensuring Optimal Care for All Children at Risk of Developing Serious Respiratory Syncytial Virus Disease: A Canadian Nurses’ Perspective  Journal Articles
• Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants  Journal Articles
• Increased Risk of RSV Infection in Children with Down's Syndrome: Clinical Implementation of Prophylaxis in the European Union  Journal Articles
• Interactions of viral pathogens on hospital admissions for pneumonia, croup and chronic obstructive pulmonary diseases: results of a multivariate time-series analysis  Journal Articles
• Lower respiratory infections in early life are linked to later asthma  Journal Articles
• Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010  Journal Articles
• Nasal cathelicidin is expressed in early life and is increased during mild, but not severe respiratory syncytial virus infection  Journal Articles
• Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data  Journal Articles
• Optimal implementation of an Ontario nirsevimab program for respiratory syncytial virus (RSV) prophylaxis: Recommendations from a provincial RSV expert panel.  Journal Articles
• Optimizing risk factors to guide COST-effective use of palivizumab in KOREAN infants.  Journal Articles
• Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy  Journal Articles
• Palivizumab Adherence and Outcomes in Canadian Aboriginal Children  Journal Articles
• Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes  Journal Articles
• Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?  Journal Articles
• Pediatric Investigators Collaborative Network on Infections in Canada Study of Respiratory Syncytial Virus–associated Deaths in Pediatric Patients in Canada, 2003–2013  Journal Articles
• Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic  Journal Articles
• Perspective: the potential of wastewater-based surveillance as an economically feasible game changer in reducing the global burden of pediatric respiratory syncytial virus infection  Journal Articles
• Practical Resources for Nurses and Other Health Care Providers Involved in the Care of Children at Risk for Respiratory Syncytial Virus Infection  Journal Articles
• Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada  Conferences
• Predictors of Poor Outcomes Among Infants With Respiratory Syncytial Virus–associated Acute Lower Respiratory Infection in Botswana  Journal Articles
• Prioritising respiratory syncytial virus prevention in low-income and middle-income countries  Journal Articles
• Re: “Completed Weeks of Gestation and Risk of Respiratory Syncytial Virus in Late Preterm Infants”  Journal Articles
• Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.  Journal Articles
• Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada  Journal Articles
• Respiratory Syncytial Virus Preterm (32–36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland  Journal Articles
• Respiratory Syncytial Virus Prophylaxis in Down Syndrome: A Prospective Cohort Study  Journal Articles
• Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children  Journal Articles
• Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017  Journal Articles
• Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab  Journal Articles
• Respiratory Syncytial Virus in Otherwise Healthy Prematurely Born Infants: A Forgotten Majority  Journal Articles
• Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations  Journal Articles
• Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab  Journal Articles
• Respiratory syncytial virus (RSV) infection in children with medical complexity  Journal Articles
• Respiratory syncytial virus nosocomial outbreak in neonatal intensive care: A review of the incidence, management, and outcomes  Journal Articles
• Respiratory syncytial virus prophylaxis for children with chronic lung disease: have we got the criteria right?  Journal Articles
• Respiratory syncytial virus prophylaxis in children with cardiac disease: a retrospective single-centre study  Journal Articles
• Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005–2016)  Journal Articles
• Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders  Journal Articles
• Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries  Journal Articles
• Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention  Journal Articles
• Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants  Journal Articles
• Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks’ gestational age in Canada  Journal Articles
• Seasonal Respiratory Syncytial Virus Prophylaxis Based on Predetermined Dates Versus Regional Surveillance Data  Journal Articles
• Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention  Journal Articles
• Special populations: Do we need evidence from randomized controlled trials to support the need for respiratory syncytial virus prophylaxis?  Journal Articles
• Strategies for Reducing the Risk of Respiratory Syncytial Virus Infection in Infants and Young Children: A Canadian Nurses’ Perspective  Journal Articles
• The Pediatric Investigators Collaborative Network on Infections in Canada Study of Predictors of Hospitalization for Respiratory Syncytial Virus Infection for Infants Born at 33 Through 35 Completed Weeks of Gestation  Journal Articles
• The Real‐Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut  Journal Articles
• The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence  Journal Articles
• The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic  Journal Articles
• The cost effectiveness of palivizumab: a systematic review of the evidence  Journal Articles
• The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis  Journal Articles
• The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus  Journal Articles
• The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study  Journal Articles
• Third human challenge trial conference, Oxford, United Kingdom, February 6–7, 2020, a meeting report  Journal Articles
• Value of a risk scoring tool to predict respiratory syncytial virus disease severity and need for hospitalization in term infants  Journal Articles
• Viral infections in the elderly  Journal Articles
• Wastewater-based surveillance identifies start to the pediatric respiratory syncytial virus season in two cities in Ontario, Canada  Journal Articles